Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 August 2021 | Story André Damons | Photo Charl Devenish
Ebeth Grobbelaar is a Scientific Manager in the South African Doping Control Laboratory (SADoCoL) who is responsible for the review and approval of results at SADoCoL, to ensure compliance with the technical requirements of the World Anti-Doping Agency (WADA).

For Ebeth Grobbelaar, Scientific Manager in the South African Doping Control Laboratory (SADoCoL) – which is housed by the University of the Free State (UFS) – her work at the laboratory is profound, as fairness on and off the playing field is vital to her.

“Creating a fair playing field for athletes to compete carries a heavy responsibility, as an anti-doping violation impacts the athlete’s career,” says Grobbelaar, who is responsible for the review and approval of results at SADoCoL to ensure compliance with the technical requirements of the World Anti-Doping Agency (WADA).

Women are the cogs in the wheel

According to her, anabolic steroids, the multiple analytical disciplines, and rapidly changing technical requirements from WADA have attracted her to the sciences of anti-doping. Sixty percent of her colleagues at SADoCoL are women.  “They are the cogs in the wheel, ensuring the laboratory's smooth operation, taking daily challenges in their stride, and excelling in what they do as analysts and administrative staff,” says Grobbelaar.

Grobbelaar says there are many options in the anti-doping field for women inside and outside of the laboratory. Some of the most influential people in the anti-doping community are women – in their roles as laboratory directors, leading researchers, directors of athlete passport management units for international sports federations, or national anti-doping agencies in various capacities.

With all the responsibilities, come challenges and pressure – especially in a year when the Olympic Games take place. 

Women should learn how to say ‘no’ 

“An Olympic year always has additional stress due to the large number of samples before the games. This year, the pressure is more, with not all accredited laboratories operational, as well as disrupted testing schedules due to COVID-19.  Enabling athletes to compete in fairness on the world stage is a responsibility and a privilege.”

“My faith is my anchor.  As far as possible, I try to leave my work behind when I leave the laboratory, and concentrate on enjoyable things such as gardening, my dog, reading, and walking with my dog. On challenging days, something sweet also helps,” explains Grobbelaar the pressure and how she copes with it. 

This Women’s Month, Grobbelaar says, women should learn how to say ‘no’ to create time for rest and play. Says Grobbelaar: “For many women, ‘doing your best’ or saying yes means working yourself to the point of a mental and physical breakdown. Having the courage to say no, loving oneself through rest and play, replenishing our spirits, and realising that we are unique and precious in God’s eyes, is a challenge that many women face.” 

“Rest and play can take different forms, such as having coffee with a friend or being creative.  The important thing is that your rest or play activity brings joy to your soul and energises you. Ask your friends to support and assist you,” she concludes. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept